Topics

High-grade gliomas | Treatment | Clinical trials | Nivolumab

Home > Publications > Topics > High-grade gliomas > Treatment > Clinical trials > Nivolumab

Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L, Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S, Neyns B.
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
Neuro Oncol. 2024 Oct 16:noae177. doi: 10.1093/neuonc/noae177. PMID: 39406392. Interventional study. ˍ

Kesari S, Wojcinski A, Pabla S, Seager RJ, Gill JM, Carrillo JA, Wagle N, Park DJ, Nguyen M, Truong J, Takasumi Y, Chaiken L, Chang SC, Barkhoudarian G, Kelly DF, Juarez TM.
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas.
Oncoimmunology. 2024 Nov 21;13(1):2432728. doi: 10.1080/2162402X.2024.2432728. PMID: 39572979. Interventional study. ˍ

Sahebjam S, Raval RR, Forsyth PA, Enderling H, Tran ND, Arrington JA, Macaulay R, Perlow HK, Palmer JD, Ghose J, Rajappa P, Giglio P, Li Z, Etame AB, Mokhtari S, Cruz-Chamorro RJ, Bhandari M, Thapa R, Robinson TJ, Chen DT, Yu HM.
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas.
Neurooncol Adv. 2025 Feb 8;7(1):vdaf033. doi: 10.1093/noajnl/vdaf033. PMID: 40134851. Interventional study. ˍ

Nguyen MK, Jelinek M, Singh A, Isett B, Myers ES, Mullett SJ, Eisele Y, Beumer JH, Parise RA, Urban J, Rose A, Sellitto L, Singh K, Doerfler R, Dadey RE, Kim C, Rhee JC, Davar D, Villaruz LC, Burgess M, Drappatz J, Mantica M, Goodman AE, Wang H, Singhi AD, Luke JJ, Zandberg DP, Bao R.
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
Oncologist. 2025 Oct 25:oyaf362. doi: 10.1093/oncolo/oyaf362. PMID: 41138165. Interventional study. ˍ